![André Choulika](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
André Choulika
Fondatore presso
CELLECTIS S.A.
Patrimonio netto: 3 M $ in data 30/06/2026
Profilo
André Choulika is the founder.
He founded Cellectis SA in 1999 and currently holds the title of Chief Executive Officer & Director.
He also founded Calyxt, Inc. in 2010 and served as Chairman until 2020.
In addition to his founding positions, Dr. Choulika currently holds several other roles.
Since 2014, he has been the Chairman & Chief Executive Officer of Cellectis, Inc. He also serves as Chairman & Chief Executive Officer of Cellectis Biologics, Inc. since 2019.
Furthermore, Dr. Choulika is the Director of Institut Pasteur and a Director of the France Biotech Association.
Previously, Dr. Choulika held a position as Director at Takara Bio Europe AB. Dr. Choulika obtained his doctorate degree from Université Pierre et Marie Curie in 1995.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
CELLECTIS S.A. 1,46% | 15/02/2026 | 1.054.914 ( 1,46% ) | 3 M $ | 30/06/2026 |
Posizioni attive di André Choulika
| Società | Posizione | Inizio |
|---|---|---|
| CELLECTIS S.A. | Fondatore | 20/12/1999 |
France Biotech Association
 France Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates an organisation for growth of health industry | Direttore/Membro del Consiglio | 06/08/2013 |
Cellectis, Inc.
 Cellectis, Inc. Pharmaceuticals: MajorHealth Technology Engages in the upstream research of genome engineering and in the development of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers | Amministratore Delegato | 01/12/2014 |
Institut Pasteur
 Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Direttore/Membro del Consiglio | 01/06/2019 |
Cellectis Biologics, Inc.
 Cellectis Biologics, Inc. Medical DistributorsDistribution Services Part of Cellectis SA, Cellectis Biologics, Inc. is a clinical-stage biopharmaceutical company that specializes in developing allogeneic cancer therapies using proprietary gene-editing technologies. The company is based in NC. Cellectis harnesses the immune system to target and eradicate cancer cells, utilizing their flagship technology and PulseAgile electroporation system. The company aims to develop a new generation of immunotherapy product candidates with enhanced safety and efficacy attributes, capable of overcoming mechanisms that inhibit immune system activity. Cellectis is dedicated to addressing the medical and food needs of a growing population and upholding good corporate governance. André Choulika has been the CEO of the company since 2019. | Amministratore Delegato | 01/01/2019 |
Precedenti posizioni note di André Choulika
| Società | Posizione | Fine |
|---|---|---|
Calyxt, Inc.
 Calyxt, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as clinical-stage biotechnology company, engages in development and commercialization of products derived from plant cells | Fondatore | 06/07/2020 |
Takara Bio Europe AB
 Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Develops hepatocytes and cardiomyocytes from the proprietary stem cells | Direttore/Membro del Consiglio | - |
Formazione di André Choulika
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
72
Relazioni di 1° grado
8
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 8 |
|---|---|
Institut Pasteur
Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Miscellaneous |
Cellectis SA
 Cellectis SA Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops immunotherapies | Health Technology |
Université Pierre et Marie Curie
 Université Pierre et Marie Curie Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
France Biotech Association
France Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates an organisation for growth of health industry | Commercial Services |
Takara Bio Europe AB
Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Develops hepatocytes and cardiomyocytes from the proprietary stem cells | Commercial Services |
Cellectis, Inc.
Cellectis, Inc. Pharmaceuticals: MajorHealth Technology Engages in the upstream research of genome engineering and in the development of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers | Health Technology |
Calyxt, Inc.
Calyxt, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as clinical-stage biotechnology company, engages in development and commercialization of products derived from plant cells | Commercial Services |
Cellectis Biologics, Inc.
Cellectis Biologics, Inc. Medical DistributorsDistribution Services Part of Cellectis SA, Cellectis Biologics, Inc. is a clinical-stage biopharmaceutical company that specializes in developing allogeneic cancer therapies using proprietary gene-editing technologies. The company is based in NC. Cellectis harnesses the immune system to target and eradicate cancer cells, utilizing their flagship technology and PulseAgile electroporation system. The company aims to develop a new generation of immunotherapy product candidates with enhanced safety and efficacy attributes, capable of overcoming mechanisms that inhibit immune system activity. Cellectis is dedicated to addressing the medical and food needs of a growing population and upholding good corporate governance. André Choulika has been the CEO of the company since 2019. | Distribution Services |
